镓-68标记DOTA-GPFAPI-04与氟-18标记FDG在实体瘤患者中的头对头诊断效能比较:一项前瞻性临床研究结果
该前瞻性研究纳入26例经组织学确诊的实体瘤患者,在连续两天分别行[68Ga]Ga-DOTA-GPFAPI-04与[18F]F-FDG PET/CT显像,以组织学诊断和随访结果为金标准,头对头比较两种示踪剂的诊断效能与背景摄取模式。结果显示[68Ga]Ga-DOTA-GPFAPI-04对腹盆腔播散灶的灵敏度高于[18F]F-FDG(1.000 vs 0.475,P<0.001),而[18F]F-FDG对肺转移灶的灵敏度更高(0.845 vs 0.682,P=0.003);尽管腺体摄取明显,该FAP靶向示踪剂仍表现出良好的诊断性能。
要点
- 26例实体瘤患者连续两日分别行[68Ga]Ga-DOTA-GPFAPI-04与[18F]F-FDG PET/CT头对头比较。
- 前者对腹盆腔播散灶灵敏度1.000 vs 后者0.475(P<0.001);后者对肺转移0.845 vs 前者0.682(P=0.003)。
- 甲状腺、胰腺、下颌下腺见明显腺体摄取,心肌与子宫肌层摄取为血池和肝背景的2–3倍。
核心结论
- 尽管存在明显的腺体摄取,[68Ga]Ga-DOTA-GPFAPI-04仍表现出良好的诊断性能。
- 作者认为[68Ga]Ga-DOTA-GPFAPI-04是有前景的探针骨架,可用于进一步开发FAP靶向肿瘤诊疗一体化药物。
研究设计与样本
- 前瞻性临床研究,纳入26例经组织学证实的实体瘤患者,包括鼻咽癌5例、食管癌5例、胃食管交界癌1例、胃癌7例、肝癌3例、结直肠癌5例。
- 患者连续数日分别接受[68Ga]Ga-DOTA-GPFAPI-04与[18F]F-FDG PET/CT扫描。
- 主要终点为诊断效能,以组织学诊断和随访结果为金标准;次要终点为背景摄取模式。
- 由两名对金标准结果设盲但了解临床背景的核医学科医师阅片并共识标注病灶,随后软件辅助分割;背景器官由人工智能辅助自动分割。
- 记录所有分割区域的体积、平均和最大标准摄取值(SUVmean和SUVmax);P<0.05视为有统计学意义。
主要发现
- 在甲状腺、胰腺和下颌下腺检测到[68Ga]Ga-DOTA-GPFAPI-04的明显腺体摄取,腮腺为中度摄取。
- 心肌和子宫肌层的放射性示踪剂摄取比血池和肝脏背景水平高2–3倍。
- 共分割349个靶病灶,包括324个恶性和25个良性病灶。
- [68Ga]Ga-DOTA-GPFAPI-04对腹盆腔播散灶的灵敏度高于[18F]F-FDG(1.000 vs 0.475,P<0.001)。
- [18F]F-FDG对肺转移灶的灵敏度高于[68Ga]Ga-DOTA-GPFAPI-04(0.845 vs 0.682,P=0.003);高腺体摄取使邻近器官病灶难以勾画,并掩盖了这些器官中的2个转移灶。
关键数值与推荐
- 主要终点诊断效能以组织学诊断和随访结果作为金标准。
- 腹盆腔播散灶灵敏度:[68Ga]Ga-DOTA-GPFAPI-04为1.000,[18F]F-FDG为0.475(P<0.001)。
- 肺转移灶灵敏度:[18F]F-FDG为0.845,[68Ga]Ga-DOTA-GPFAPI-04为0.682(P=0.003)。
- 统计学显著性阈值定为P<0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 高腺体摄取使邻近器官病灶难以勾画,并掩盖了这些器官中的2个转移灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify the biodistribution and diagnostic performance of a novel fibroblast activation protein (FAP) targeted positron emission tomography (PET) tracer, [68Ga]Ga-DOTA-GPFAPI-04, in patients with solid tumors in a head-to-head comparison with [18F]F-FDG. METHODS: Twenty-six patients histologically proven with cancers of nasopharyngeal (n = 5), esophagus (n = 5), gastro-esophagus (n = 1), stomach (n = 7), liver (n = 3), and colorectum (n = 5) were recruited for [68Ga]Ga-DOTA-GPFAPI-04 and [18F]F-FDG PET/CT scans on consecutive days. The primary endpoint was the diagnostic efficacy, with the histological diagnosis and the follow-up results selected as the gold standard. The secondary endpoint was the background uptake pattern. Two experienced nuclear medicine physicians who were blinded to the gold standard results while having essential awareness of the clinical context reviewed the images and labeled lesions by consensus for subsequent software-assisted lesion segmentation. Additionally, background organs were automatically segmented, assisted by artificial intelligence. Volume, mean, and maximum standard uptake values (SUVmean and SUVmax) of all segmentations were recorded. P < 0.05 was deemed as statistically significant. RESULTS: Significant glandular uptake of [68Ga]Ga-DOTA-GPFAPI-04 was detected in the thyroid, pancreas, and submandibular glands, while moderate uptake was observed in the parotid glands. The myocardium and myometrium exhibited 2-3 times higher uptake of the radiotracer than that of the background levels in blood and liver. A total of 349 targeted lesions, consisting of 324 malignancies and 25 benign lesions, were segmented. [68Ga]Ga-DOTA-GPFAPI-04 is more sensitive than [18F]F-FDG, especially for abdominopelvic dissemination (1.000 vs. 0.475, P < 0.001). Interestingly, [18F]F-FDG demonstrated higher sensitivity for lung metastasis compared to [68Ga]Ga-DOTA-GPFAPI-04 (0.845 vs. 0.682, P = 0.003). The high glandular uptake made it difficult to delineate lesions in close proximity and masked two metastatic lesions in these organs. CONCLUSION: Despite prominent glandular uptake, [68Ga]Ga-DOTA-GPFAPI-04 demonstrates favorable diagnostic performance. It is a promising probe scaffold for further development of FAP-targeted tumor theranostic agents.
引用
- Yuan H, Liu E, Zhang G, et al. Diagnostic efficacy of [68Ga]Ga-DOTA-GPFAPI-04 in patients with solid tumors in a head-to-head comparison with [18F]F-FDG: results from a prospective clinical study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38727829. doi:10.1007/s00259-024-06756-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。